A Phase 2 interventional study of HT-0712 and Placebo in Age-Associated Memory Impairment (AAMI), sponsored by Dart NeuroScience, LLC. Completed at 16 sites in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-12-30.
Sponsored by Dart NeuroScience, LLC · Phase 2, Interventional, and Treatment
This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)
Main Inclusion Criteria:
Main Exclusion Criteria:
HT-0712 capsules administered once daily.
Drug: HT-0712
Placebo capsules administered once daily.
Drug: Placebo
Cognitive Drug Research™ (CDR) Study Specific Test Battery
Time frame: Weekly over the course of 6-weeks
Paired Associated Learning and Memory Test
Time frame: Weekly over the course of 6-weeks
Subject Global Impression Scale of Cognition (SGI-Cog)
Time frame: Weekly over the course of 6-weeks
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dart NeuroScience, LLC